158 related articles for article (PubMed ID: 38526046)
1. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR; Soriano A; Honore PM; Bassetti M; Cornely OA; Kollef M; Kullberg BJ; Pullman J; Hites M; Fortún J; Horcajada JP; Kotanidou A; Das AF; Sandison T; Aram JA; Vazquez JA; Pappas PG
Lancet Infect Dis; 2024 Mar; 24(3):319-328. PubMed ID: 38008099
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
6. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR; Soriano A; Cornely OA; Kullberg BJ; Kollef M; Vazquez J; Honore PM; Bassetti M; Pullman J; Chayakulkeeree M; Poromanski I; Dignani C; Das AF; Sandison T; Pappas PG;
Lancet; 2023 Jan; 401(10370):49-59. PubMed ID: 36442484
[TBL] [Abstract][Full Text] [Related]
7. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.
Kullberg BJ; Viscoli C; Pappas PG; Vazquez J; Ostrosky-Zeichner L; Rotstein C; Sobel JD; Herbrecht R; Rahav G; Jaruratanasirikul S; Chetchotisakd P; Van Wijngaerden E; De Waele J; Lademacher C; Engelhardt M; Kovanda L; Croos-Dabrera R; Fredericks C; Thompson GR
Clin Infect Dis; 2019 May; 68(12):1981-1989. PubMed ID: 30289478
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
10. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
13. Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections.
Deorukhkar SC; Saini S
Infect Disord Drug Targets; 2016; 16(1):63-8. PubMed ID: 26648186
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
15. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
[TBL] [Abstract][Full Text] [Related]
16. Proof of Concept for MBT ASTRA, a Rapid Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS)-Based Method To Detect Caspofungin Resistance in Candida albicans and Candida glabrata.
Vatanshenassan M; Boekhout T; Lass-Flörl C; Lackner M; Schubert S; Kostrzewa M; Sparbier K
J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 30021820
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
Bader JC; Lakota EA; Flanagan S; Ong V; Sandison T; Rubino CM; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555634
[TBL] [Abstract][Full Text] [Related]
18. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Thompson GR; Soriano A; Skoutelis A; Vazquez JA; Honore PM; Horcajada JP; Spapen H; Bassetti M; Ostrosky-Zeichner L; Das AF; Viani RM; Sandison T; Pappas PG
Clin Infect Dis; 2021 Dec; 73(11):e3647-e3655. PubMed ID: 32955088
[TBL] [Abstract][Full Text] [Related]
19. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
20. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]